TobiasWalbertMD

Neurology • Detroit, MI

Neurooncology, Hospice and Palliative Medicine

Associate Professor, Neurology, Wayne State University SOM

Join to view full profile

Dr. Walbert is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Walbert's full profile

Already have an account?

Office
2799 W. Grand Boulevard
Detroit, MI 48202
Phone+1 313-916-2723

Education & Training

University of Texas M D Anderson Cancer CenterFellowship, Neuro-Oncology, 2008 - 2010
Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Neurology, 2005 - 2008
Case Western Reserve University/University Hospitals Cleveland Medical CenterInternship, Internal Medicine, 2004 - 2005
OtherClass of 2000

Certifications & Licensure

FL State Medical License 2021 - Present
MI State Medical License 2009 - 2026
OH State Medical License 2004 - 2008
American Board of Internal Medicine Hospice and Palliative Medicine
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Start of enrollment: 2009 Jun 01
Completed
Phase 3
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma Start of enrollment: 2015 Nov 30
Terminated
Phase 2, Phase 3
Terameprocol in Treating Patients With Recurrent High Grade Glioma Start of enrollment: 2018 May 03
Completed
Phase 1
Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas Start of enrollment: 2018 Oct 30
Terminated
Phase 1
Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer Start of enrollment: 2018 Jul 09
Recruiting
Phase 1
Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2017 Jun 07
Terminated
Phase 1
MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Start of enrollment: 2019 Sep 29
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma.
Christopher L Moertel, Angela C Hirbe, Hans H Shuhaiber, Kevin Bielamowicz, Alpa Sidhu
Journal of Clinical Oncology. 2024-11-08
Lisavanbulin (BAL101553), a novel microtubule inhibitor, plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma.
Matthias Holdhoff, Xiaobu Ye, Roy E Strowd, Burt Nabors, Tobias Walbert
Neuro-Oncology Advances. 2024-08-28
Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT.
Manmeet S Ahluwalia, Ahmad Ozair, Jan Drappatz, Xiaobu Ye, Sen Peng
Clinical Cancer Research. 2024-08-01

Press Mentions

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Looking to Fill Glioblastoma Multiforme Treatment Gap with Berubicin Drug ProductAugust 30th, 2022
Henry Ford Health Researchers Launch Clinical Trial Studying Therapy Aimed at Causing Brain Cancer Cells to Self-DestructJune 10th, 2023